Florida-based biopharma Longeveron ($LGVN@US), which is developing cell therapies for chronic age-related and life-threatening conditions, announced Friday results for a mid-stage study of its lead candidate. One-third of the U.S. Veterans above 65 years have frailty, and therefore, these results are clinically significant and relevant. Longeveron said it plans to review the trial data during an upcoming steering committee comprised of independent frailty experts and plan its next steps for the program. Currently, there are no FDA-approved therapies that can slow down, reverse, or prevent aging frailty. LGVN shares are up 34% on Friday's pre-market.